» Articles » PMID: 33765515

A Free Mailed Naloxone Program in Philadelphia Amidst the COVID-19 Pandemic

Overview
Publisher Elsevier
Date 2021 Mar 25
PMID 33765515
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Access to naloxone is essential as the overdose crisis persists. We described barriers to accessing naloxone among individuals who requested and received the medication from a free mailed program and explored the relationship between how individuals with and without personal proximity to overdose learned about the program.

Methods: Secondary analysis of data from a web-based form collected 1st March 2020 to 31st January 2021. Access barriers, personal proximity to overdose (broadly defined as personally overdosing or witnessing/worrying about others overdosing), and method of learning about the program were categorized and described.

Results: Among 422 respondents, the most frequently reported barriers to accessing naloxone were: COVID quarantine (25.1%), lack of knowledge about access (13.2%), and cost (11.2%). Compared to those without personal proximity to overdose (38.2%), individuals with personal proximity (61.8%) heard about the program more often through an active online search (21.4% vs. 8.8%; p-value = 0.001) and less often through word of mouth (19.8% vs. 40.9%; p-value = <0.001).

Conclusions: Longstanding barriers to naloxone access are compounded by the COVID-19 pandemic, making mailing programs especially salient. Differences in ways that individuals with and without personal proximity to substance use and overdose learned about this program can inform how such programs can effectively reach their target audience.

Citing Articles

Perspectives of key interest groups regarding supervised Consumption sites (SCS) and novel virtual harm reduction services / overdose response hotlines and applications: a qualitative Canadian study.

Seo B, Rioux W, Teare A, Rider N, Jones S, Taplay P Harm Reduct J. 2024; 21(1):141.

PMID: 39068494 PMC: 11282589. DOI: 10.1186/s12954-024-01053-3.


Exploration of weekly variation in naloxone possession and carriage among people who use opioids in New York City before, during, and after the COVID-19 pandemic.

Roth A, Ward K, Hensel D, Elliott L, Bennett A PLoS One. 2024; 19(7):e0307151.

PMID: 39024257 PMC: 11257247. DOI: 10.1371/journal.pone.0307151.


Virtual opioid poisoning education and naloxone distribution programs: A scoping review.

Dos Santos B, Farzan Nipun R, Maria Subic A, Kubica A, Rondinelli N, Marentette D PLOS Digit Health. 2024; 3(6):e0000412.

PMID: 38848374 PMC: 11161022. DOI: 10.1371/journal.pdig.0000412.


Development of a systematic social observation tool for monitoring use of harm reduction supplies.

Nesoff E, Aronowitz S, Milam A, Furr-Holden C Int J Drug Policy. 2023; 122:104235.

PMID: 37890392 PMC: 10842406. DOI: 10.1016/j.drugpo.2023.104235.


A cost benefit analysis of a virtual overdose monitoring service/mobile overdose response service: the national overdose response service.

Rioux W, Enns B, Jackson J, Quereshi H, Irvine M, Ghosh S Subst Abuse Treat Prev Policy. 2023; 18(1):57.

PMID: 37794482 PMC: 10548617. DOI: 10.1186/s13011-023-00565-8.


References
1.
Tsai A, Kiang M, Barnett M, Beletsky L, Keyes K, McGinty E . Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019; 16(11):e1002969. PMC: 6957118. DOI: 10.1371/journal.pmed.1002969. View

2.
Adams J, Volkow N . Ethical Imperatives to Overcome Stigma Against People With Substance Use Disorders. AMA J Ethics. 2020; 22(1):E702-708. DOI: 10.1001/amajethics.2020.702. View

3.
Khatri U, Perrone J . Opioid Use Disorder and COVID-19: Crashing of the Crises. J Addict Med. 2020; 14(4):e6-e7. PMC: 7236857. DOI: 10.1097/ADM.0000000000000684. View

4.
Yang C, Favaro J, Meacham M . NEXT Harm Reduction: An Online, Mail-Based Naloxone Distribution and Harm-Reduction Program. Am J Public Health. 2021; 111(4):667-671. PMC: 7958031. DOI: 10.2105/AJPH.2020.306124. View

5.
Fadanelli M, Cloud D, Ibragimov U, Ballard A, Prood N, Young A . People, places, and stigma: A qualitative study exploring the overdose risk environment in rural Kentucky. Int J Drug Policy. 2019; 85:102588. PMC: 7231629. DOI: 10.1016/j.drugpo.2019.11.001. View